The Top 5 Biosimilar Articles for the Week of May 31

Video

Here are the top 5 biosimilar articles for the week of May 31, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of May 31, 2021.

Number 5: BioFactura has begun a phase 1 clinical trial for an ustekinumab biosimilar candidate (BFI-751) referencing Stelara, an immunosuppressant for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

Number 4: More transparency in how health care money is spent could improve utilization and efficiency, panelists said at the Medicines for Europe event.

Number 3: Investigators reporting on insulin availability in the Philippines said affordability and access are inadequate for many in the country and recommended measures for improvement.

Number 2: Febrile neutropenia (FN) in patients undergoing chemotherapy has long been counteracted with granulocyte colony-stimulating factor (G-CSF) drugs. Models of G-CSF biosimilar use in this setting suggest not only significant savings but also potential for expanded access.

Number 1: Biosimilar manufacturers may encounter roadblocks in the months and years ahead, and generics manufacturers will find they've hit a ceiling, according to Adam Fein, PhD, CEO of the Drug Channels Institute.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Chelsee Jensen, PharmD, BCPS
Here are the top 5 biosimilar articles for the week of November 20, 2023.
Here are the top 5 biosimilar articles for the week of November 13, 2023.
GBW 2023 webinar
Ryan Haumschild, PharmD, MS, MBA
Here are the top 5 biosimilar articles for the week of October 30, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.